Background Curcumin inhibits the growth of esophageal cancer cell lines; however, the mechanism of action is not well understood. It is becoming increasingly clear that aberrant activation of Notch signaling has been associated with the development of esophageal cancer. Here, we have determined that curcumin inhibits esophageal cancer growth via a mechanism mediated through the Notch signaling pathway. Methodology/Principal Findings In this study, we show that curcumin treatment resulted in a dose and time dependent inhibition of proliferation and colony formation in esophageal cancer cell lines. Furthermore, curcumin treatment induced apoptosis through caspase 3 activation, confirmed by an increase in the ratio of Bax to Bcl2. Cell cycle analysis demonstrated that curcumin treatment induced cell death and down regulated cyclin D1 levels. Curcumin treatment also resulted in reduced number and size of esophagospheres. Furthermore, curcumin treatment led to reduced Notch-1 activation, expression of Jagged-1 and its downstream target Hes-1. This reduction in Notch-1 activation was determined to be due to the down-regulation of critical components of the γ-secretase complex proteins such as Presenilin 1 and Nicastrin. The combination of a known γ-secretase inhibitor DAPT and curcumin further decreased proliferation and induced apoptosis in esophageal cancer cells. Finally, curcumin treatment down-regulate the expressions of Notch-1 specific microRNAs miR-21 and miR-34a, and upregulated tumor suppressor let-7a miRNA. Conclusion/Significance Curcumin is a potent inhibitor of esophageal cancer growth that targets the Notch-1 activating γ-secretase complex proteins. These data suggest that Notch signaling inhibition is a novel mechanism of action for curcumin during therapeutic intervention in esophageal cancers.
References
[1]
Dawsey SP, Tonui S, Parker RK, Fitzwater JW, Dawsey SM, et al. (2010) Esophageal cancer in young people: a case series of 109 cases and review of the literature. PLoS One 5: e14080.
[2]
Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, et al. (2008) Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 122: 1118–1129.
[3]
Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212–236.
[4]
Liao S, Xia J, Chen Z, Zhang S, Ahmad A, et al. (2011) Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways. J Cell Biochem 112: 1055–1065.
[5]
O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR, Piwocka K, McKenna SL (2009) Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer 101: 1585–1595.
[6]
Hartojo W, Silvers AL, Thomas DG, Seder CW, Lin L, et al. (2010) Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol 3: 99–108.
[7]
Tian F, Song M, Xu PR, Liu HT, Xue LX (2008) [Curcumin promotes apoptosis of esophageal squamous carcinoma cell lines through inhibition of NF-kappaB signaling pathway]. Ai Zheng 27: 566–570.
[8]
Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, et al. (2006) Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442: 823–826.
[9]
Peters JH, Avisar N (2010) The molecular pathogenesis of Barrett's esophagus: common signaling pathways in embryogenesis metaplasia and neoplasia. J Gastrointest Surg 14: Suppl 1S81–87.
[10]
Masuda S (2011) Dysfunctional transforming growth factor-beta signaling with constitutively active notch signaling in Barrett's esophageal adenocarcinoma. Cancer.
[11]
Miele L (2006) Notch signaling. Clin Cancer Res 12: 1074–1079.
[12]
Miele L, Golde T, Osborne B (2006) Notch signaling in cancer. Curr Mol Med 6: 905–918.
[13]
Miele L, Miao H, Nickoloff BJ (2006) NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6: 313–323.
[14]
Katoh M (2007) Notch signaling in gastrointestinal tract (review). Int J Oncol 30: 247–251.
[15]
Yao J, Duan L, Fan M, Wu X (2007) Gamma-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells. Oral Dis 13: 555–563.
[16]
Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004) Processing of primary microRNAs by the Microprocessor complex. Nature 432: 231–235.
[17]
Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.
[18]
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, et al. (2008) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27: 2128–2136.
[19]
Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, et al. (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677–4684.
[20]
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647–658.
[21]
Bansal A, Lee IH, Hong X, Anand V, Mathur SC, et al. (2011) Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am J Gastroenterol 106: 1055–1063.
[22]
Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193–199.
[23]
Wang Z, Li Y, Kong D, Ahmad A, Banerjee S, et al. (2010) Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 292: 141–148.
[24]
Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, et al. (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569–7576.
[25]
Lee ST, Chu K, Oh HJ, Im WS, Lim JY, et al. (2011) Let-7 microRNA inhibits the proliferation of human glioblastoma cells. J Neurooncol 102: 19–24.
[26]
Landegren U (1984) Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. J Immunol Methods 67: 379–388.
[27]
Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6: 24.
[28]
Su CC, Lin JG, Li TM, Chung JG, Yang JS, et al. (2006) Curcumin-induced apoptosis of human colon cancer colo 205 cells through the production of ROS, Ca2+ and the activation of caspase-3. Anticancer Res 26: 4379–4389.
[29]
Wang Z, Azmi AS, Ahmad A, Banerjee S, Wang S, et al. (2009) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 69: 2757–2765.
[30]
Li H, Wolfe MS, Selkoe DJ (2009) Toward structural elucidation of the gamma-secretase complex. Structure 17: 326–334.
[31]
Wolfe MS (2009) gamma-Secretase in biology and medicine. Semin Cell Dev Biol 20: 219–224.
[32]
Gong P, Vetrivel KS, Nguyen PD, Meckler X, Cheng H, et al. (2010) Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates. J Biol Chem 285: 38042–38052.
[33]
Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, et al. (2011) Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep 31: 185–197.
[34]
Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, et al. (2008) Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7: 464–473.
[35]
Yang J, Cao Y, Sun J, Zhang Y (2010) Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 27: 1114–1118.
[36]
Saini S, Arora S, Majid S, Shahryari V, Chen Y, et al. (2011) Curcumin modulates microRNA-203 mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev Res (Phila).
[37]
Zhang J, Du Y, Wu C, Ren X, Ti X, et al. (2010) Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 24: 1217–1223.
[38]
Ushida J, Sugie S, Kawabata K, Pham QV, Tanaka T, et al. (2000) Chemopreventive effect of curcumin on N-nitrosomethylbenzylamine-induced esophageal carcinogenesis in rats. Jpn J Cancer Res 91: 893–898.
[39]
Yu L, Wu WK, Li ZJ, Wong HP, Tai EK, et al. (2008) E series of prostaglandin receptor 2-mediated activation of extracellular signal-regulated kinase/activator protein-1 signaling is required for the mitogenic action of prostaglandin E2 in esophageal squamous-cell carcinoma. J Pharmacol Exp Ther 327: 258–267.
[40]
Ashworth T, Roy AL (2009) Phase specific functions of the transcription factor TFII-I during cell cycle. Cell Cycle 8: 596–605.
Mendelson J, Song S, Li Y, Maru DM, Mishra B, et al. (2011) Dysfunctional transforming growth factor-beta signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer 117: 3691–3702.
[43]
Woo SM, Kim J, Han HW, Chae JI, Son MY, et al. (2009) Notch signaling is required for maintaining stem-cell features of neuroprogenitor cells derived from human embryonic stem cells. BMC Neurosci 10: 97.
[44]
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, et al. (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425–436.
[45]
Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, et al. (2010) Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 70: 3606–3617.
[46]
Si ML, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor growth. Oncogene 26: 2799–2803.
[47]
Hu Y, Correa AM, Hoque A, Guan B, Ye F, et al. (2011) Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer 128: 132–143.
[48]
Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, et al. (1997) Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 71: 79–87.
[49]
Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, et al. (2011) Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. Oncogene 30: 2587–2594.
[50]
Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, et al. (2003) Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52: 174–180.
[51]
Dong Q, Meng P, Wang T, Qin W, Qin W, et al. (2010) MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5: e10147.
[52]
Vandenboom TG Ii, Li Y, Philip PA, Sarkar FH (2008) MicroRNA and Cancer: Tiny Molecules with Major Implications. Curr Genomics 9: 97–109.
[53]
Bao B, Wang Z, Ali S, Kong D, Li Y, et al. (2011) Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307: 26–36.
